ESMO 2022: spotlight on new emerging treatment options in central nervous system tumors Invited short review

被引：1
作者：
Mair, Maximilian J. [1 ]
Berghoff, Anna S. [1 ]
机构：
[1] Med Univ Vienna, Dept Med 1, Div Oncol, Waehringer Guertel 18-20, A-1090 Vienna, Austria
来源：
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY | 2023年 / 16卷 / 02期
关键词：
CNS neoplasms; Glioma; Glioblastoma; Targeted therapy; Immunotherapy; PHASE-II; GLIOBLASTOMA; RADIOTHERAPY; COMBINATION; BEVACIZUMAB; LOMUSTINE; DELIVERY;
D O I：
10.1007/s12254-023-00879-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Nearly 40 abstracts regarding tumors of the central nervous system were presented at the European Society for Medical Oncology (ESMO) Congress in September 2022. While no practice-changing data were shown, interesting early phase clinical trial results on immune-modulating agents, targeted treatments and other therapeutic modalities were revealed (Table 1). In this short review, we aim to summarize our personal highlights of the presented data and outline future perspectives in the field.
引用
收藏
页码：100 / 104
页数：5
相关论文
共 20 条
  • [1] Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial
    Bartsch, Rupert
    Berghoff, Anna Sophie
    Furtner, Julia
    Marhold, Maximilian
    Bergen, Elisabeth Sophie
    Roider-Schur, Sophie
    Starzer, Angelika Martina
    Forstner, Heidrun
    Rottenmanner, Beate
    Dieckmann, Karin
    Bago-Horvath, Zsuzsanna
    Haslacher, Helmuth
    Widhalm, Georg
    Ilhan-Mutlu, Aysegul
    Minichsdorfer, Christoph
    Fuereder, Thorsten
    Szekeres, Thomas
    Oehler, Leopold
    Gruenberger, Birgit
    Singer, Christian F.
    Weltermann, Ansgar
    Puhr, Rainer
    Preusser, Matthias
    [J]. NATURE MEDICINE, 2022, 28 (09) : 1840 - +
  • [2] Targeted inducible delivery of immunoactivating cytokines reprograms glioblastoma microenvironment and inhibits growth in mouse models
    Birocchi, Filippo
    Cusimano, Melania
    Rossari, Federico
    Beretta, Stefano
    Rancoita, Paola M., V
    Ranghetti, Anna
    Colombo, Stefano
    Costa, Barbara
    Angel, Peter
    Sanvito, Francesca
    Callea, Marcella
    Norata, Rossana
    Chaabane, Linda
    Canu, Tamara
    Spinelli, Antonello
    Genua, Marco
    Ostuni, Renato
    Merelli, Ivan
    Coltella, Nadia
    Naldini, Luigi
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2022, 14 (653)
  • [3] The ReSPECT-GBM™ phase I/IIa trial of rhenium-186 nanoliposome (186RNL) in recurrent glioma via convection enhanced delivery (CED) and planned phase IIb trial
    Brenner, A. J.
    Phillips, W. T.
    Bao, A.
    Hedrick, M. H. H.
    Michalek, J. E.
    LaFrance, N.
    Patel, T. R.
    Weinberg, J.
    Floyd, J. R.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S666 - S666
  • [4] Buxton MB, 2020, J CLIN ONCOL, V38
  • [5] Preliminary results of a phase II study of retifanlimab (PD-1 inhibitor) plus or minus epacadostat (IDO1 inhibitor) in combination with bevacizumab and hypofractionated radiotherapy for recurrent glioblastoma: NCT03532295
    Campian, J. L.
    Butt, O.
    Huang, J.
    Luo, J.
    Tao, Y.
    Strowd, R.
    Hissim, D.
    Kizilbash, S. H.
    Abraham, C.
    Ansstas, G.
    Johanns, T.
    Kim, A.
    Ciorba, M.
    Chheda, M.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S666 - S666
  • [6] Targeting the tumor microenvironment of glioblastoma multiforme using a macrophage-based treatment for the local delivery of immune-therapeutic payload: The TEM-GBM study (NCT03866109)
    Finocchiaro, G.
    Eoli, M.
    Farina, F.
    Gentner, B.
    Capotondo, A.
    Anghileri, E.
    Bruzzone, M.
    D'Alessandris, Q. G.
    Franzin, A.
    Ferroli, P.
    Gagliardi, F.
    Legnani, F.
    Mazzoleni, S.
    Olivi, A.
    Pallini, R.
    Saini, M.
    Zambanini, A.
    Naldini, L.
    Russo, C.
    Ciceri, F.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S669 - S669
  • [7] Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells
    Klemm, Florian
    Maas, Roeltje R.
    Bowman, Robert L.
    Kornete, Mara
    Soukup, Klara
    Nassiri, Sina
    Brouland, Jean-Philippe
    Iacobuzio-Donahue, Christine A.
    Brennan, Cameron
    Tabar, Viviane
    Gutin, Philip H.
    Daniel, Roy T.
    Hegi, Monika E.
    Joyce, Johanna A.
    [J]. CELL, 2020, 181 (07) : 1643 - +
  • [8] Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
    Lim, Michael
    Weller, Michael
    Idbaih, Ahmed
    Steinbach, Joachim
    Finocchiaro, Gaetano
    Raval, Raju R.
    Ansstas, George
    Baehring, Joachim
    Taylor, Jennie W.
    Honnorat, Jerome
    Petrecca, Kevin
    De Vos, Filip
    Wick, Antje
    Sumrall, Ashley
    Sahebjam, Solmaz
    Mellinghoff, Ingo K.
    Kinoshita, Masashi
    Roberts, Mustimbo
    Slepetis, Ruta
    Warad, Deepti
    Leung, David
    Lee, Michelle
    Reardon, David A.
    Omuro, Antonio
    [J]. NEURO-ONCOLOGY, 2022, 24 (11) : 1935 - 1949
  • [9] During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium
    Melder, RJ
    Koenig, GC
    Witwer, BP
    Safabakhsh, N
    Munn, LL
    Jain, RK
    [J]. NATURE MEDICINE, 1996, 2 (09) : 992 - 997
  • [10] Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143
    Omuro, Antonio
    Vlahovic, Gordana
    Lim, Michael
    Sahebjam, Solmaz
    Baehring, Joachim
    Cloughesy, Timothy
    Voloschin, Alfredo
    Ramkissoon, Shakti H.
    Ligon, Keith L.
    Latek, Robert
    Zwirtes, Ricardo
    Strauss, Lewis
    Paliwal, Prashni
    Harbison, Christopher T.
    Reardon, David A.
    Sampson, John H.
    [J]. NEURO-ONCOLOGY, 2018, 20 (05) : 674 - 686
12